True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
South San Francisco, US
15 (est)-6%

Key People at True North Therapeutics

Nancy Stagliano

Nancy Stagliano


True North Therapeutics Locations

South San Francisco, US

True North Therapeutics Metrics

True North Therapeutics Summary

Founding Date


Total Funding

$142 M

Latest funding size

$45 M

Time since last funding

5 days


Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Baxter Ventures, OrbiMed, Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, MPM Capital, SR One, OrbiMed, Baxalta Ventures

True North Therapeutics News

True North Therapeutics Company Life